Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

What to do about aspirin in type 2 diabetes?

December 19th 2016

NICE guidance (NG28) released on 15th December 2015 changed the advice regarding aspirin use to: ‘Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.’ This has raised the question as to whether patients already taking aspirin, in line with the previous NICE clinical guideline (CG87), should now stop (although NICE did not specifically recommend this action).

The guideline development group for NG28 focused on three studies of antiplatelet therapies, two of which provided new evidence. One was an unpublished post-hoc analysis of cardiovascular (CV) outcomes in the Early Treatment Diabetic Retinopathy Study and the second from a Japanese population, with notoriously low levels of CV events. The doses of aspirin used ranged from 61-650 mg, and the quality of the evidence was rated as between ‘moderate’ and ‘very low’.

New, high quality evidence will appear in the near future. NICE acknowledged the UK-based ASCEND trial, which includes 15,480 people with diabetes without occlusive arterial disease, which is scheduled to continue until 2017. NICE also highlighted another trial (ACCEPT-D) conducted in Italy which also aims to assess the effects of low-dose aspirin on major vascular events in people with diabetes and no clinical evidence of vascular disease. For this reason, NICE did not recommend further research in this area.

Other guidelines do not support change. The American Diabetes Association ‘Standards of Care’ 2016 continues to recommend consideration ‘of aspirin therapy (75–162 mg/day) as a primary prevention strategy in those with type 1 or type 2 diabetes who are at increased CV risk (10-year risk >10%). This includes most men or women with diabetes aged 50 years who have at least one additional major risk factor’- remarkably similar to CG87.

There is also evidence in the literature of a rebound effect from stopping aspirin i.e. an increased risk of ischaemic stroke in patients four weeks after discontinuation. Furthermore, duration of aspirin use is not a risk factor for bleeding, that is to say those patients who are established on aspirin are at low risk of its major side-effect.

This balance of risks should make practitioners very wary of change.

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Sanofi DiabetesNovo NordiskAstraZenecaNapp Diabetes

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Amgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership